Disc Medicine, Inc. (NasdaqGM: IRON)
Health Care · Biotechnology · US
$59.89
-7.16% today · -6.9% 1Y
Disc Medicine, Inc. (NasdaqGM: IRON) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.48B and employs 165 people.
Over the last twelve months the share price has lost 6.9%, trading between 40.00 and 99.50.
Tweenvest scores Disc Medicine, Inc. across four factors: quality 65/100, value 39/100. Its strongest factor is quality.
IRON price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.48B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -6.56
- Dividend yield
- —
- Beta (5Y)
- 2.05
- 52-week high
- $99.50
- 52-week low
- $40.00
- Avg volume (3M)
- —
- Shares outstanding
- 38.39M
- Employees
- 165
- Next earnings
- —
About Disc Medicine, Inc.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
- ISIN
- US2546041011
- Founded
- 2017
- Listed since
- Aug 12, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| BGI Genomics Co., Ltd.SZSE: 300676 | $2.62B | CN¥45.86 | +1.64% |
| Sinocelltech Group LimitedSHSE: 688520 | $2.60B | CN¥37.05 | +3.64% |
| Zealand Pharma A/SCPSE: ZEAL | $2.54B | Dkr237.00 | -4.97% |
| Bavarian Nordic A/SCPSE: BAVA | $2.53B | Dkr230.00 | +3.05% |
| Beam Therapeutics Inc.NasdaqGS: BEAM | $2.48B | $24.20 | -2.30% |
| Celldex Therapeutics, Inc.NasdaqCM: CLDX | $2.39B | $29.00 | -4.70% |
| Nurix Therapeutics, Inc.NasdaqGM: NRIX | $2.39B | $22.08 | -3.96% |
| Immunome, Inc.NasdaqCM: IMNM | $2.37B | $19.04 | -8.90% |
Figures last refreshed Oct 4, 2026.